Targeting these factors can significantly impact the treatment of specific malignancies, as exemplified by the clinical success of agents targeting the androgen receptor (AR) in prostate cancer and estrogen receptor (ER) in breast cancer36. This evidence concerns the gene ESR1 and Familial prostate cancer.